Cipla Q1 FY2026 Results: Total Revenue Hits ₹7,119 Cr; Net Profit after Tax Stands at ₹787 Cr

Cipla Q1 FY2026 Results: Total Revenue Hits ₹7,119 Cr; Net Profit after Tax Stands at ₹787 Cr​

Cipla Ltd has released its unaudited financial results for the quarter ended June 30, 2026. The company reported total revenue from operations of ₹7,119.28 Crores in the consolidated segment, alongside a net profit after tax of ₹787.10 Crores.

The Q1 FY2026 performance saw Cipla generate Total Income of ₹7,330.18 Crores, compared to ₹6,541.20 Crores in the corresponding quarter of FY2025, and ₹7,216.03 Crores in Q1 FY24.

Key Financial Highlights (Consolidated)​

The results demonstrate consistent activity across sales and operational income streams:

• Total Revenue from Operations: ₹7,119.28 Cr (Q1 FY26), up from ₹6,541.20 Cr (Q1 FY25).
• Other Income: Increased to ₹210.90 Crores in Q1 FY26.
• Total Expenses: Consolidated expenses stood at ₹6,248.25 Crores, down from ₹5,982.30 Crores in Q1 FY25.
• Net Profit After Tax (NPAT): The company posted a Net Profit after Tax of ₹787.10 Crores for the quarter.
• Total Comprehensive Income: For the quarter, Total Comprehensive Income was reported at ₹979.61 Crores.

The following table details the key components of Cipla’s consolidated financial performance:

Standalone Performance and Equity Changes​

The unaudited standalone financial results for the quarter also showed a strong performance profile:

• Standalone Revenue from Operations: ₹5,077.68 Crores (Q1 FY26).
• Net Profit After Tax (NPAT): The company recorded NPAT of ₹862.16 Crores in the standalone segment for the quarter.
• Basic Earnings Per Share (EPS): Standalone Basic EPS was reported at ₹10.67 per share.

In terms of capital structure, Cipla’s paid-up equity share capital increased to ₹161.57 Crores during the quarter, resulting from the allotment of shares through the "ESOS 2013 -A" and 'Cipla ESAR Scheme 2021' schemes.

Operational Updates and Corporate Events​

The company reported several key operational events:

• Labour Code Impact: An incremental gratuity liability aggregating ₹244.37 Crores was recognized in the financial results under an Exceptional Item, following the implementation of 'New Labour Codes' effective November 21, 2025. This expense was incurred due to revised definitions of 'wages'.
• Impairment: The Group recorded an impairment of ₹31.00 Crores in Q1 FY26 related to a change in business conditions and market dynamics concerning an associate.
• M&A Activity: Cipla’s Board of Directors approved the Scheme of Amalgamation for Inzpera Healthsciences Limited, a wholly owned subsidiary, with the company. The scheme is currently awaiting necessary approvals from the National Company Law Tribunal (NCLT), Mumbai.

Litigation and Associate Exposure​

Cipla provided detailed information regarding ongoing litigation related to drug overcharging by the National Pharmaceutical Pricing Authority (NPPA). The aggregate amount covered by demand notices received, after removing duplications, stood at ₹2,011 Crores, comprising ₹863 Crores as principal and ₹1,148 Crores in interest.

The company also noted that it has been legally advised regarding its expected favourable outcome concerning the related party demands amounting to ₹9.96 Crores from Okasa Pharma Private Limited and Okasa Limited. These specific demands are subject to a Business Transfer Agreement between Okasa and a Cipla subsidiary, which excludes DPCO liability.

CIPLA Stock Price Movement​

As of 12:11 PM, shares of Cipla Limited are climbing slightly in live trading, currently valued at ₹1415.2 after gaining ₹0.10, or 0.01%. With over one million shares changing hands today, the stock maintains solid activity as it trades within its tight intraday range.